Title: Detailed explanation of the pharmacological effects and clinical applications of captopril

First paragraph: content overview
Captopril is the first angiotensin-converting enzyme inhibitor (ACEI) to be marketed and is mainly used to treat hypertension and heart failure. This article will start fromPharmacological mechanism,Indications,Usage and dosage,adverse reactionsandManufacturerExpand in five aspects. The core content focuses on its mechanism of action by inhibiting the production of angiotensin II and reducing peripheral vascular resistance. It also emphasizes the need to be wary of side effects such as dry cough and hyperkalemia. The secondary content covers clinical combination drug regimens and production information of different dosage forms.

Paragraph 2: Pharmacological mechanism and core functions
Captopril specifically inhibits the ACE enzyme and blocks the conversion of angiotensin I to angiotensin II.dilate arteries,Reduce aldosterone secretion. In 1981, the FDA approved it for the treatment of hypertension, and clinical data show that it can reduce systolic blood pressure by an average of 10-15mmHg (Source: "New England Journal of Medicine"). its uniqueThiol structureIt takes effect quickly (takes effect in 15 minutes after oral administration), especially suitable for hypertensive emergencies. In addition, it can reduce cardiac pre- and post-load and improve the prognosis of patients with heart failure.

Paragraph 3: Clinical Application and Precautions
According to the "China Guidelines for the Prevention and Treatment of Hypertension", the recommended starting dose of captopril is 12.5 mg bid, and the maximum dose should not exceed 150 mg/day. Note:Patients with renal insufficiency need to reduce the dose, combined with diuretics may enhance the antihypertensive effect. Typical adverse reactions include dry cough (incidence rate is about 20%), rash and abnormal taste. Contraindications include bilateral renal artery stenosis, pregnancy, and allergies to sulfa drugs. The American Heart Association (AHA) recommends regular monitoring of potassium and creatinine levels during medication.

Paragraph 4: Dosage Form and Production Information
The main domestic dosage forms include regular tablets (25mg/tablet) and sustained-release tablets. The following is information about major manufacturers and product names:

In 2019, the price selected by the national centralized procurement was 0.05 yuan/tablet (25mg specification), which greatly improved the accessibility of medication (data source: National Medical Insurance Administration).

Paragraph 5: Summary and Outlook
As a classic ACEI drug, captopril still plays an important role in the stepwise treatment of hypertension. Its price advantage is significant and it is especially suitable for primary medical use. However, it should be noted that with the popularity of ARB drugs, their clinical application is gradually shifting to specific groups (such as patients with diabetic nephropathy). Future research directions include the development of new drug delivery systems and more precise personalized medication regimens.

Quote sources:
1. "New England Journal of Medicine" 1982 special report on ACE inhibitors
2. U.S. FDA drug package insert (NDA 18-343)
3. Chinese Pharmacopoeia 2020 Edition Part 2
4. National Drug Administration drug database (approval number H19990236)